Recent Price Movement and Market Context
On 5 Mar 2026, Biofil Chemicals & Pharmaceuticals Ltd’s share price fell to Rs.28.01, underperforming the Pharmaceuticals & Biotechnology sector by 0.82%. This decline comes despite a broadly positive market environment, with the Sensex opening higher at 79,530.48 points, gaining 414.29 points (0.52%) before settling at 79,256.86, still up 0.18% on the day. Notably, the Sensex is trading below its 50-day moving average but maintains a positive technical stance as the 50DMA remains above the 200DMA. Mega-cap stocks are leading the market gains, contrasting with the weaker performance of mid and small caps such as Biofil Chemicals.
Biofil Chemicals is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained downward momentum. The stock’s 52-week high was Rs.56.36, highlighting a steep decline of over 50% from its peak within the last year.
Financial Performance and Fundamental Metrics
The company’s financial indicators reveal ongoing challenges. Over the past five years, Biofil Chemicals has experienced a compound annual growth rate (CAGR) decline of 50.89% in operating profits, reflecting weakening earnings capacity. The average EBIT to interest coverage ratio stands at a low 0.12, signalling limited ability to comfortably service debt obligations. Return on equity (ROE) has averaged 5.27%, a modest figure that points to subdued profitability relative to shareholders’ funds.
Quarterly earnings per share (EPS) have also been under pressure, with the latest reported EPS at Rs.0.05, the lowest in recent quarters. The company’s flat results in the December 2025 quarter further underscore the absence of meaningful earnings growth.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Comparative Performance and Market Positioning
Biofil Chemicals has consistently underperformed against the broader market and its sector peers. Over the last year, the stock has delivered a negative return of 37.92%, in stark contrast to the Sensex’s positive 7.81% gain over the same period. Furthermore, the stock has lagged behind the BSE500 index in each of the past three annual periods, highlighting persistent relative weakness.
Despite these challenges, the company’s valuation metrics present a nuanced picture. With an ROE of 13 and a price-to-book value ratio of 2.4, Biofil Chemicals is trading at a discount relative to its peers’ historical averages. The company’s profits have risen by 217% over the past year, a notable increase that contrasts with the stock’s price decline. This divergence is reflected in a low PEG ratio of 0.1, suggesting that the market is pricing in subdued growth expectations.
Shareholding and Market Capitalisation
The majority of Biofil Chemicals’ shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company’s market capitalisation grade is rated 4, indicating a relatively modest size within its sector. The Mojo Score assigned to the stock is 23.0, with a Mojo Grade of Strong Sell as of 16 Feb 2026, an upgrade from the previous Sell rating. This reflects a deteriorated outlook based on fundamental and technical factors.
Holding Biofil Chemicals & Pharmaceuticals Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
To summarise, Biofil Chemicals & Pharmaceuticals Ltd’s recent stock price decline to Rs.28.01 marks a new 52-week low amid a backdrop of weak long-term earnings growth, limited debt servicing capacity, and subdued profitability. The stock’s technical indicators remain bearish, trading below all major moving averages. While the company’s valuation metrics suggest some discount relative to peers, the persistent underperformance against benchmark indices and sector averages continues to weigh on investor sentiment.
Market conditions remain mixed, with broader indices showing resilience led by mega-cap stocks, whereas smaller and mid-cap stocks such as Biofil Chemicals face ongoing headwinds. The company’s shareholding structure dominated by non-institutional investors may also impact trading patterns and liquidity.
Conclusion
Biofil Chemicals & Pharmaceuticals Ltd’s fall to its 52-week low reflects a combination of fundamental and technical factors that have contributed to sustained price weakness. The stock’s recent performance and financial metrics highlight the challenges faced by the company within the Pharmaceuticals & Biotechnology sector. Investors and market participants will continue to monitor the stock’s trajectory in the context of broader market trends and sector developments.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
